The shareholder conference call of the Extraordinary General Meeting of Mainstay Medical Holdings PLC is scheduled to commence on the 23rd of February 2024. Documents to Review: Reinstated Constitution of Mainstay Medical Holdings PLC

Time of Conference:

4PM GMT (Ireland)
11AM ET/10AM CT (USA)

CLICK TO REGISTER

Corporate Governance

The Board recognizes the importance of good governance in supporting growth in long term shareholder value and is accordingly committed to maintaining the highest standards of corporate governance commensurate with the size and stage of the development of the Group.

While there is no specific corporate governance regime mandated in Ireland for companies listed on ESM nor is there any specific corporate governance regime mandated in France for companies who are listed on Euronext but not incorporated in France, the Company applies recognized corporate governance principles to the extent they are appropriate for a company of its size, stage of development and resources.

The Board will also take account of other institutional shareholder governance guidelines on disclosure and shareholder authorizations to the extent they are appropriate for a company of its size, stage of development and resources.

The Board of Directors

The Board is responsible for the supervision and control of the Company and is accountable to the Company. The Board has reserved decision-making on a variety of matters, including determining strategy for the Group, reviewing and monitoring executive management performance and monitoring risks and controls.

The Board comprises nine Directors, including one Executive Director, seven Non-Executive Directors and the Non-Executive Chairman. The roles of Chairman and Chief Executive Officer are not exercised by the same individual.

The Board meets regularly (no less than four times per year) to consider strategy, performance and the framework of internal controls. The Directors have also established an Audit, Risk and Compliance Committee, a Remuneration Committee, and a Nominations Committee with formally delegated rules and responsibilities. Each of the Committees currently comprises Non-Executive Directors only.

The Board comprises a mix of the necessary skills, knowledge and experience required to provide leadership, control and oversight of the management of the Company and to contribute to the development and implementation of the Company’s strategy. In particular, the Board combines a group of Directors with diverse backgrounds within the medical device and related sectors, in both public and private companies.

All the Directors bring independent judgment to bear on issues affecting the Group and all have full and timely access to information necessary to enable them to discharge their duties. The Articles require each Director retire at the annual general meeting held in the third calendar year following the year in which he was appointed or last re-appointed but unless he falls within the paragraph immediately below he shall be eligible for re-appointment.

A Director shall also retire at any annual general meeting if he has agreed to do so (whether in accordance with the terms of his appointment or otherwise) and, unless the Directors have agreed otherwise, he shall not be eligible for re-appointment.

This section serves as notice under 35 U.S.C. §287(a) that the following products are protected by one or more U.S. patents. Each product also may be covered by one or more foreign patents, and additional patent application(s) may be pending.
The following list of products and U.S. patents may not be all inclusive, and other products not listed here may be protected by one or more patents.
ReActiv8 is covered by one or more of the following U.S. patents: 8,428,728; 8,606,358; 9,072,897; 9,474,906; 9,861,811; 9,999,763; 10,016,603; 10,195,419; 10,327,810; 10,449,355; 10,828,490; 10,925,637; 11,103,706; 11,331,488; 11,471,670; 11,679,261; 11,679,262; 11,684,774; 11,786,725; 11,951,310 as well as their international equivalents. Other patents pending.